Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) (7625ACNPhase3)

NCT03830333 PHASE3 COMPLETED Results posted

This study aims to evaluate the efficacy of ceftolozane/tazobactam (MK-7625A) plus metronidazole versus meropenem in adults diagnosed with complicated intra-abdominal infection (cIAI). The primary hypothesis is ceftolozane/tazobactam plus metronidazole is non-inferior to meropenem, as measured by the clinical response rate at the Test-of Cure (TOC) visit in the Clinically Evaluable (CE) population.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	PHASE3
Status	COMPLETED
Enrolment	268
Start date	Wed Mar 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Complicated Intra-abdominal Infections

Interventions

• Ceftolozane/Tazobactam
• Metronidazole
• Meropenem
• Placebo

Countries

China